Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18657109 | 1.00 | MMP2 (0.45) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL3345460 | 1.00 | MMP2 (0.45) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL14685401 | 0.97 | MMP2 (0.44) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL2297429 | 0.97 | MMP2 (0.44) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL14439895 | 0.95 | MMP2 (0.43) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL5926169 | 0.95 | ANPEP (0.41) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL13512916 | 0.95 | ANPEP (0.41) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL12284558 | 0.93 | ANPEP (0.50) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL1121964 | 0.93 | ANPEP (0.50) | MMP2ANPEPNPC1CYP3A4KDM4E | |
| SCHEMBL12347419 | 0.92 | MMP2 (0.40) | MMP2ANPEPNPC1CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-10 | — | — | US | disclosed |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| EP-4039280-A1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | Seagen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-12-31 | — | — | US | disclosed |
| EP-3470086-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-11-05 | — | — | US | disclosed |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2020-10-13 | — | — | US | disclosed |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| EP-3470086-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2019-04-17 | — | — | EP | disclosed |
| EP-2906248-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2018-12-05 | — | — | EP | disclosed |
| WO-2011130598-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| US-20110256157-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110196148-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2350080-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | Spirogen Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| WO-2010043877-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010010347-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | CD79B, BCL6B, BCL6 | MMP2 4461/4885ANPEP 1326/4885NPC1 3743/4885 |
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | MMP2 4579/4885ANPEP 2198/4885NPC1 4493/4885 |
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | GRIN2C, ZKSCAN2, ZRANB2 | MMP2 4664/4885ANPEP 2194/4885NPC1 970/4885 |
| US-20110196148-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | CCND2, CCNH, CCND1 | MMP2 4610/4885ANPEP 4291/4885NPC1 2473/4885 |
| US-20110256157-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | HDAC10, PBDC1, PDCD10 | MMP2 4553/4885ANPEP 3214/4885NPC1 1320/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | MMP2 4461/4885ANPEP 1326/4885NPC1 3743/4885 |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | HCRTR2, HCRTR1, CBR3 | MMP2 4802/4885ANPEP 4620/4885NPC1 3213/4885 |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD4, IL2 | MMP2 4579/4885ANPEP 2198/4885NPC1 4493/4885 |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | PSMA2, PSMA7, FOLH1 | MMP2 2958/4885ANPEP 81/4885NPC1 3370/4885 |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | MMP2 4579/4885ANPEP 2198/4885NPC1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.